Aurobindo Pharma

Aurobindo Pharma Limited is an Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana. Founded in 1986 by a group of entrepreneurs led by P. V. Ramprasad Reddy, the company has grown into one of India's largest pharmaceutical manufacturers and a major global supplier of generic medicines. Aurobindo develops, manufactures and markets a broad portfolio of formulations, active pharmaceutical ingredients (APIs) and intermediates, with a strong presence in anti-infectives, cardiovascular, central nervous system (CNS), anti-diabetics, anti-allergics, gastroenterology and other therapeutic categories. The company operates across the entire pharmaceutical value chain, from API synthesis to finished dosage forms, and is vertically integrated with manufacturing facilities in India and several other countries. Aurobindo is a significant player in the United States generics market, where it ranks among the top generic pharmaceutical companies by prescriptions, and it also has a substantial presence in Europe, particularly through its subsidiary Aurobindo Pharma B.V. and its operations in the Netherlands, Portugal and other European countries. Its products are sold in over 150 countries. Aurobindo is listed on the Bombay Stock Exchange and the National Stock Exchange of India under the ticker AUROPHARMA. The company has pursued growth through both organic expansion and strategic acquisitions, including the acquisition of certain assets from Actavis in Europe and the acquisition of Apotex's operations in several European countries. It has also invested in biosimilars, injectables and specialty pharmaceuticals through its subsidiaries and research and development efforts. In recent years, Aurobindo has focused on expanding its complex generics portfolio, increasing its research and development spending, and strengthening its presence in regulated markets. The company operates a large manufacturing base with multiple US FDA-approved facilities and has faced regulatory scrutiny at some of its plants, which it has worked to address. Aurobindo remains a key player in the global generic pharmaceutical industry and a major contributor to India's pharmaceutical exports.

Aurobindo Pharma was founded in 1986 in Hyderabad, India, by a group of entrepreneurs including P. V. Ramprasad Reddy, K. Nithyananda Reddy and Penaka Sarath Chandra Reddy. The company began as a manufacturer of active pharmaceutical ingredients (APIs) and gradually expanded into finished dosage formulations. In its early years, Aurobindo focused on the Indian market and on exporting APIs to regulated and semi-regulated markets. During the 1990s and 2000s, Aurobindo expanded its manufacturing capabilities and obtained approvals from major regulatory authorities, including the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This allowed the company to enter the lucrative US and European generics markets. Aurobindo grew through a combination of organic expansion and acquisitions. In 2006, it acquired Milpharm Limited in the UK, and in 2007 it acquired Pharmacin International B.V. in the Netherlands. These acquisitions strengthened its European presence. A major turning point came in 2014 when Aurobindo acquired the generics business of Actavis in seven European countries (including France, Italy, Spain, Portugal, the Netherlands, Belgium and Germany) for approximately €30 million. This acquisition significantly expanded its European footprint and product portfolio. In 2015, Aurobindo acquired Apotex's operations in five European countries (Czech Republic, Poland, Romania, Slovakia and the Netherlands), further consolidating its position in Europe. In the United States, Aurobindo became one of the largest generic pharmaceutical companies by prescription volume, benefiting from the wave of patent expirations and the growing demand for affordable medicines. The company invested heavily in research and development, with a focus on complex generics, injectables, biosimilars and specialty products. It also expanded its API business, becoming one of the world's leading API manufacturers. Aurobindo has faced regulatory challenges at some of its manufacturing facilities. In 2017 and subsequent years, the US FDA issued observations and warning letters for certain plants, including its Unit III and Unit VII facilities in Hyderabad and its API plant in Srikakulam. The company has since implemented corrective actions and remediation measures. Despite these challenges, Aurobindo continued to grow, and by the 2020s it was among the top generic pharmaceutical companies globally, with revenues exceeding US$2 billion. In recent years, Aurobindo has focused on expanding its injectables and biosimilars portfolio, increasing its presence in China and other emerging markets, and investing in new manufacturing capacities. The company has also been working on developing complex products such as oncology drugs and respiratory medicines. Aurobindo remains a family-promoted company, with the founding Reddy family holding a significant stake, and it is listed on the Bombay Stock Exchange and the National Stock Exchange of India.

• 2015

  Acquired Apotex operations in five European countries.

• 2014

  Acquired Actavis generics business in seven European countries.

• 2007

  Acquired Pharmacin International B.V. in the Netherlands.

• 2006

  Acquired Milpharm Limited in the UK.

• 1986

  Aurobindo Pharma founded in Hyderabad, India.

Vertically integrated, cost-competitive global generic pharmaceutical manufacturer with a broad portfolio and strong presence in regulated markets.

• Anti-infectives

  A broad range of antibiotics and antiviral products.

• Cardiovascular drugs

  Medicines for hypertension, heart failure and related conditions.

• CNS drugs

  Products for neurological and psychiatric disorders.

• Anti-diabetics

  Oral and injectable diabetes treatments.

• Injectables

  Sterile injectable formulations including antibiotics.

• Biosimilars

  Biologic products similar to approved reference biologics.

• 2020

  Aurobindo Pharma and others sued over alleged metformin contamination concealment

  MSP Recovery filed a class action in a U.S. court against Aurobindo Pharma and other drug makers, alleging concealment of information about the cancer-causing agent NDMA in metformin. The article reports that Valisure's tests found NDMA in metformin produced by Aurobindo and Heritage, while also noting that Aurobindo passed the FDA test for NDMA presence.

  Source

• 2020

  Astellas files patent-infringement complaint against pharmaceutical companies

  Astellas Pharma Inc. and affiliated plaintiffs filed a complaint in Delaware against 21 pharmaceutical companies, alleging that their proposed generic versions of Myrbetriq would infringe the '780 patent. The plaintiffs sought court relief; the allegations are claims in the complaint.

  Source

Read more

• 2026.01.01

  Reported2026.01.01

  Aurobindo Pharma acquires Khandelwal Laboratories' non-oncology prescription business for Rs 325 crore[5]阿拉宾度制药以3.25亿卢比收购Khandelwal Laboratories非肿瘤处方药业务timesofindia.indiatimes.com

  Aurobindo Pharma, through its wholly owned subsidiary Auro Pharma Limited, acquired the non-oncology prescription business of Mumbai-based Khandelwal Laboratories Pvt Ltd on a going concern, slump sale basis for a cash consideration of Rs 325 crore, effective January 1, 2026. The acquired business comprises 23 established brands across 67 SKUs and nine pipeline products in pain management and anti-infective segments, with a turnover of Rs 113.5 crore, and is supported by a field force of approximately 470 personnel and over 1,600 stockists across India.

• 2021.08.13

  Reported2021.08.13

  Aurobindo Pharma announces investment for 51% stake in Cronus[6]Aurobindo Pharma宣布投资收购Cronus 51%股权equitybulls.com

  Aurobindo Pharma entered into definitive agreements to subscribe to fresh equity shares in Cronus for Rs. 420 Crores, subject to closing conditions. Following the investment, Aurobindo Pharma would own 51% of Cronus's equity share capital.

• 2020.11.24

  Reported2020.11.26

  Astellas files patent-infringement complaint against pharmaceutical companies[4]Astellas files patent-infringement complaint against pharmaceutical companieslawstreetmedia.com

  Astellas Pharma Inc. and affiliated plaintiffs filed a complaint in Delaware against 21 pharmaceutical companies, alleging that their proposed generic versions of Myrbetriq would infringe the ’780 patent. The plaintiffs sought court relief; the allegations are claims in the complaint.

• 2020.09.15

  Reported2020.09.15

  Aurobindo collaborates with CSIR laboratories on COVID-19 vaccines[7]Aurobindo与CSIR实验室合作开发新冠疫苗thehindu.com

  Aurobindo said it will undertake the clinical development and commercialisation of COVID-19 vaccine candidates being developed by three CSIR laboratories: CSIR-CCMB, CSIR-IMTech and IICB.

• 2020.04.03

  Reported2020.04.08

  Aurobindo Pharma and others sued over alleged metformin contamination concealment[3]Aurobindo Pharma and others sued over alleged metformin contamination concealmentbusinesstoday.in

  MSP Recovery filed a class action in a U.S. court against Aurobindo Pharma and other drug makers, alleging concealment of information about the cancer-causing agent NDMA in metformin. The article reports that Valisure’s tests found NDMA in metformin produced by Aurobindo and Heritage, while also noting that Aurobindo passed the FDA test for NDMA presence.

Read more

1. 1Aurobindo Pharma Official Websiteaurobindo.com
2. 2Aurobindo Pharma - Wikipediaen.wikipedia.org
3. 3Aurobindo Pharma and others sued over alleged metformin contamination concealmentbusinesstoday.in
4. 4Astellas files patent-infringement complaint against pharmaceutical companieslawstreetmedia.com
5. 5阿拉宾度制药以3.25亿卢比收购Khandelwal Laboratories非肿瘤处方药业务timesofindia.indiatimes.com
6. 6Aurobindo Pharma宣布投资收购Cronus 51%股权equitybulls.com
7. 7Aurobindo与CSIR实验室合作开发新冠疫苗thehindu.com
8. 8CSIR collaborates with Aurobindo Pharma to develop Covid-19 vaccineshindustantimes.com
9. 9CSIR collaborates with Aurobindo Pharma to develop COVID-19 vaccinesaninews.in